KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities

Background/Objectives: Resistance to currently available KRAS inhibitors presents a major therapeutic challenge in non-small cell lung cancer (NSCLC). The purpose of this review is to describe the various mechanisms of resistance to KRAS inhibitors, including the activation of an epithelial-to-mesenchymal transition (EMT) program, tumor microenvironment modulation, and the rewiring of KRAS-addicted cancer cells towards other signaling pathways that promote growth and proliferation amidst KRAS inhibition. Results: Through a narrative review of recent and landmark studies in the field of KRAS inhibitor resistance, we summarize the primary non-genetic mechanisms of resistance to KRAS inhibitors as follows: receptor tyrosine kinase-mediated induction of both wild-type and mutant KRAS and the activation of several bypass signaling pathways, such as PI3K/AKT, Gas6/AXL, and YAP/TEAD/Hippo. Conclusions: We conclude that no single non-genetic driver of resistance is responsible for all cases of KRAS inhibitor resistance; rather, effective therapeutic strategies may also be informed by the tumor co-mutational status and the transcriptional phenotype of the tumor, including a mesenchymal or highly plastic cell state.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-13
DOI
https://doi.org/10.3390/cancers18223635
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities

Don Lynn Gibbons, Samrat T. Kundu, Sofia Garza
Cancers
Lung Cancer Treatments and Mutations
article

KRAS Inhibitor Resistance in Lung Cancer: Mechanisms and Therapeutic Opportunities

Don Lynn Gibbons, Samrat T. Kundu, Sofia Garza
article en

Abstract

Background/Objectives: Resistance to currently available KRAS inhibitors presents a major therapeutic challenge in non-small cell lung cancer (NSCLC). The purpose of this review is to describe the various mechanisms of resistance to KRAS inhibitors, including the activation of an epithelial-to-mesenchymal transition (EMT) program, tumor microenvironment modulation, and the rewiring of KRAS-addicted cancer cells towards other signaling pathways that promote growth and proliferation amidst KRAS inhibition. Results: Through a narrative review of recent and landmark studies in the field of KRAS inhibitor resistance, we summarize the primary non-genetic mechanisms of resistance to KRAS inhibitors as follows: receptor tyrosine kinase-mediated induction of both wild-type and mutant KRAS and the activation of several bypass signaling pathways, such as PI3K/AKT, Gas6/AXL, and YAP/TEAD/Hippo. Conclusions: We conclude that no single non-genetic driver of resistance is responsible for all cases of KRAS inhibitor resistance; rather, effective therapeutic strategies may also be informed by the tumor co-mutational status and the transcriptional phenotype of the tumor, including a mesenchymal or highly plastic cell state.

CancersVol. 18(22)
The University of Texas MD Anderson Cancer Center (US)
Cancer Prevention and Research Institute of Texas
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon